Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1097-1105

  Balsalobre, Luz ^a   Ferrándiz, María José ^a   De Alba, Gabriela ^a   De La Campa, Adela G ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; PROTEIN PARC; PROTEIN PARE; RECOMBINANT ENZYME;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DNA SUPERCOILING; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PLASMID; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TWO DIMENSIONAL ELECTROPHORESIS; WILD TYPE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASES; DNA TOPOISOMERASES, TYPE II; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUOROQUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 79952346568     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00783-10     Document Type: Article

References (65)

1. Adam, H. J., D. J. Hoban, A. S. Gin, and G. G. Zhanel. 2009. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int. J. Antimicrob. Agents 34:82-85.
2. Andersson, D. I., and D. Hughes. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271.
3. Bagel, S., V. Hullen, B. Wiedemann, and P. Heisig. 1999. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob. Agents Chemother. 43:868-875.
4. Balsalobre, L., and A. G. de la Campa. 2008. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes. Antimicrob. Agents Chemother. 52:822-830.
5. Balsalobre, L., M. J. Ferrándiz, J. Linares, F. Tubau, and A. G. de la Campa. 2003. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:2072-2081.
6. Bjorkholm, B., et al. 2001. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc. Natl. Acad. Sci. U. S. A. 98:14607-14612.
7. Champoux, J. J. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413.
8. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
9. Choi, E. H., et al. 2008. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14:275-281.
10. de la Campa, A. G., et al. 2009. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg. Infect. Dis. 15:905-911.
11. de la Campa, A. G., et al. 2004. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg. Infect. Dis. 10:1751-1759.
12. de la Campa, A. G., G. H. del Solar, and M. Espinosa. 1990. Initiation of replication of plasmid pLS1. The initiator protein RepB acts on two distant DNA regions. J. Mol. Biol. 213:247-262.
13. Dorman, C. J. 1991. DNA supercoiling and environmental regulation of gene expression in pathogenic bacteria. Infect. Immun. 59:745-749.
14. Drlica, K., M. Malik, R. J. Kerns, and X. Zhao. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392.
15. Ender, M., N. McCallum, R. Adhikari, and B. Berger-Bachi. 2004. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob. Agents Chemother. 48:2295-2297.
16. Feil, E. J., et al. 2001. Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc. Natl. Acad. Sci. U. S. A. 98:182-187.
17. Fenoll, A., et al. 2009. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 47:1012-1020.
18. Fernández-Moreira, E., D. Balas, I. González, and A. G. de la Campa. 2000. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb. Drug Resist. 6:259-267.
19. Ferrándiz, M. J., A. J. Martín-Galiano, J. B. Schvartzman, and A. G. de la Campa. 2010. The genome of Streptococcus pneumoniae is organized in topology-reacting gene clusters. Nucleic Acids Res. 38:3570-3581.
20. Ferrándiz, M. J., A. Fenoll, J. Liñares, and A. G. de la Campa. 2000. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:840-847.
21. Fuller, J. D., and D. E. Low. 2005. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41:118-121.
22. Gagneux, S., et al. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946. (Pubitemid 43993719)
23. Gellert, M., K. Mizuuchi, M. H. O'Dea, and H. A. Nash. 1976. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. U. S. A. 73:3872-3876.
24. Gillespie, S. H., L. L. Voelker, J. E. Ambler, C. Traini, and A. Dickens. 2003. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb. Drug Resist. 9:17-24.
25. Gmüender, H., et al. 2001. Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res. 11:28-42. (Pubitemid 32117951)
26. Houssaye, S., L. Gutmann, and E. Varon. 2002. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:2712-2715.
27. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, R. N. Grüneberg, and the Alexander Project Group. 2003. The Alexander project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.
28. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
29. Jeong, K. S., Y. Xie, H. Hiasa, and A. B. Khodursky. 2006. Analysis of pleiotropic transcriptional profiles: a case study of DNA gyrase inhibition. PLoS Genet. 2:e152.
30. Johnson, C. N., D. E. Briles, W. H. Benjamin, S. K. Hollingshead, and K. B. Waites. 2005. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg. Infect. Dis. 11:814-820.
31. Kato, J., et al. 1990. New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404.
32. Komp Lindgren, P., L. L. Marcusson, D. Sandvang, N. Frimodt-Moller, and D. Hughes. 2005. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob. Agents Chemother. 49:2343-2351.
33. Kusuma, C., A. Jadanova, T. Chanturiya, and J. F. Kokai-Kun. 2007. Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob. Agents Chemother. 51:475-482.
34. Kyaw, M. H., et al. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:1455-1463.
35. Lacks, S. A., P. López, B. Greenberg, and M. Espinosa. 1986. Identification and analysis of genes for tetracycline resistance and replication functions in the broad-host-range plasmid pLS1. J. Mol. Biol. 192:753-765.
36. Liñares, J., A. G. de la Campa, and R. Pallarés. 1999. Fluoroquinolone resistance in Streptococcus pneumoniae. N. Engl. J. Med. 341:1546-1547.
37. Luo, N., et al. 2005. Enhanced in vivo fitness of fluoroquinolone- resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci. U. S. A. 102:541-546.
38. Mandell, L. A., et al. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2):S27-S72.
39. Marcusson, L. L., N. Frimodt-Moller, and D. Hughes. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5:e1000541.
40. Martín-Parras, L., et al. 1998. Topological complexity of different populations of pBR322 as visualized by two-dimensional agarose gel electrophoresis. Nucleic Acids Res. 26:3424-3432. (Pubitemid 28321408)
41. Menzel, R., and M. Gellert. 1987. Fusions of the Escherichia coli gyrA and gyrB control regions to the galactokinase gene are inducible by coumermycin treatment. J. Bacteriol. 169:1272-1278. (Pubitemid 17043398)
42. Menzel, R., and M. Gellert. 1987. Modulation of transcription by DNA supercoiling: a deletion analysis of the Escherichia coli gyrA and gyrB promoters. Proc. Natl. Acad. Sci. U. S. A. 84:4185-4189.
43. Menzel, R., and M. Gellert. 1983. Regulation of the genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling. Cell 34:105-113. (Pubitemid 13045469)
44. Moore, M. R., et al. 2008. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197:1016-1027.
45. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
46. Nagaev, I., J. Bjorkman, D. I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40:433-439.
47. Olavarrieta, L., P. Hernández, D. B. Krimer, and J. B. Schvartzman. 2002. DNA knotting caused by head-on collision of transcription and replication. J. Mol. Biol. 322:1-6.
48. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
49. Pan, X. S., and L. M. Fisher. 1999. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43:1129-1136.
50. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:166-167.
51. Peter, B. J., et al. 2004. Genomic transcriptional response to loss of chromosomal supercoiling in Escherichia coli. Genome Biol. 5:R87.
52. Pilishvili, T., et al. 2010. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201:32-41.
53. Pruss, G., S. Manes, and K. Drlica. 1982. Escherichia coli DNA topoisomerase I mutants: increased supercoiling is corrected by mutations near gyrase genes. Cell 31:35-42. (Pubitemid 13215194)
54. Riedel, S., et al. 2007. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 26:485-490.
55. Rozen, D. E., L. McGee, B. R. Levin, and K. P. Klugman. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:412-416.
56. Rui, S., and Y. C. Tse-Dhin. 2003. Topoisomerase function during bacterial responses to environmental challenge. Front. Biosci. 8:d256-d263.
57. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
58. Stanhope, M. J., et al. 2005. Molecular evolution perspectives on intraspecific lateral DNA transfer of topoisomerase and gyrase loci in Streptococcus pneumoniae, with implications for fluoroquinolone resistance development and spread. Antimicrob. Agents Chemother. 49:4315-4326.
59. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
60. Thiara, A. S., and E. Cundliffe. 1993. Expression and analysis of two gyrB genes from the novobiocin producer, Streptomyces sphaeroides. Mol. Microbiol. 8:495-506.
61. Travers, A., and G. Muskhelishvili. 2005. DNA supercoiling - a global transcriptional regulator for enterobacterial growth? Nat. Rev. Microbiol. 3:157-169.
62. Tse-Dinh, Y. C. 1985. Regulation of the Escherichia coli DNA topoisomerase I gene by DNA supercoiling. Nucleic Acids Res. 13:4751-4763.
63. Unniraman, S., M. Chatterji, and V. Nagaraja. 2002. DNA gyrase genes in Mycobacterium tuberculosis: a single operon driven by multiple promoters. J. Bacteriol. 184:5449-5456. (Pubitemid 35024392)
64. Whitney, C. G., et al. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.
65. World and Health Organization. 2007. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly. Epidemiol. Rec. 82:93-104.